Ieq Capital LLC Buys 50,722 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Ieq Capital LLC lifted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 47.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 158,112 shares of the company’s stock after buying an additional 50,722 shares during the quarter. Ieq Capital LLC owned approximately 0.13% of 10x Genomics worth $2,270,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in TXG. Capital Performance Advisors LLP bought a new position in shares of 10x Genomics during the third quarter worth $35,000. Blue Trust Inc. boosted its holdings in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock valued at $40,000 after purchasing an additional 1,025 shares during the last quarter. Sound Income Strategies LLC boosted its holdings in shares of 10x Genomics by 65.2% during the 4th quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after purchasing an additional 1,330 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of 10x Genomics during the fourth quarter valued at about $52,000. Finally, Venturi Wealth Management LLC increased its holdings in shares of 10x Genomics by 1,108.9% in the third quarter. Venturi Wealth Management LLC now owns 2,442 shares of the company’s stock worth $55,000 after purchasing an additional 2,240 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TXG. JPMorgan Chase & Co. dropped their price target on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Citigroup cut their target price on shares of 10x Genomics from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, February 13th. UBS Group decreased their price target on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Barclays dropped their price objective on shares of 10x Genomics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Finally, The Goldman Sachs Group decreased their target price on shares of 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $20.57.

10x Genomics Stock Performance

Shares of TXG opened at $10.90 on Monday. The company has a 50 day moving average price of $14.31 and a 200-day moving average price of $17.08. 10x Genomics, Inc. has a fifty-two week low of $10.80 and a fifty-two week high of $48.42. The stock has a market capitalization of $1.33 billion, a PE ratio of -7.17 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last posted its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. Equities research analysts forecast that 10x Genomics, Inc. will post -1.43 EPS for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.